Dana E. Rathkopf
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Research top 0.2%
- Cancer, Lipids, and Metabolism
- Cancer Genomics and Diagnostics
Papers in
-
- Prostate Cancer Treatment and Research 99
- Prostate Cancer Diagnosis and Treatment 11
-
- Cancer, Lipids, and Metabolism 12
- Cancer Genomics and Diagnostics 9
- Co-authors
- Howard I. Scher (38 shared papers)Philip W. Kantoff (5 shared papers)Min Yuen Teo (1 shared paper)Michael J. Morris (21 shared papers)Daniel Costin Danila (10 shared papers)Steven M. Larson (7 shared papers)Celestia S. Higano (9 shared papers)Joshi J. Alumkal (6 shared papers)
- Journals
- Annals of Oncology (20 papers)European Urology (19 papers)Clinical Cancer Research (14 papers)Journal of Clinical Oncology (12 papers)The Journal of Urology (7 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Dana E. Rathkopf
141 papers receiving 22.0k citations
Dana E. Rathkopf's Hit Papers
Peers
Comparison fields: 5 of 128
- Pulmonary and Respiratory Medicine 14.5k
- Cancer Research 5.0k
- Oncology 5.3k
- Radiology, Nuclear Medicine and Imaging 2.6k
- Endocrinology, Diabetes and Metabolism 1.4k
Countries citing papers authored by Dana E. Rathkopf
This map shows the geographic impact of Dana E. Rathkopf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana E. Rathkopf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana E. Rathkopf more than expected).
Fields of papers citing papers by Dana E. Rathkopf
This network shows the impact of papers produced by Dana E. Rathkopf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana E. Rathkopf. The network helps show where Dana E. Rathkopf may publish in the future.
Co-authors
The 25 scholars most cited alongside Dana E. Rathkopf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 143 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Integrative Clinical Genomics of Advanced Prostate Cancer Hit paper breakdown → | 2015 | 2985 |
| 2 | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Hit paper breakdown → | 2014 | 2453 |
| 3 | Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy Hit paper breakdown → | 2012 | 2299 |
| 4 | OncoKB: A Precision Oncology Knowledge Base Hit paper breakdown → | 2017 | 1972 |
| 5 | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3 Hit paper breakdown → | 2016 | 1297 |
| 6 | Organoid Cultures Derived from Patients with Advanced Prostate Cancer Hit paper breakdown → | 2014 | 1275 |
| 7 | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Hit paper breakdown → | 2015 | 1106 |
| 8 | Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study Hit paper breakdown → | 2010 | 882 |
| 9 | Treatment of Advanced Prostate Cancer Hit paper breakdown → | 2019 | 555 |
| 10 | Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade Hit paper breakdown → | 2018 | 527 |
| 11 | Integrative Clinical Genomics of Advanced Prostate Cancer Hit paper breakdown → | 2015 | 461 |
| 12 | Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making Hit paper breakdown → | 2017 | 440 |
| 13 | Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study Hit paper breakdown → | 2016 | 341 |
| 14 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2023 | 240 |
| 15 | 2014 | 224 | |
| 16 | 2013 | 219 | |
| 17 | 2020 | 209 | |
| 18 | Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial Hit paper breakdown → | 2022 | 201 |
| 19 | 2013 | 157 | |
| 20 | 2015 | 148 |
About Dana E. Rathkopf
Dana E. Rathkopf is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Radiology, Nuclear Medicine and Imaging and Endocrinology, Diabetes and Metabolism, having authored 143 papers that have together received 22.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (99 papers), Radiopharmaceutical Chemistry and Applications (14 papers), Cancer, Lipids, and Metabolism (12 papers), Prostate Cancer Diagnosis and Treatment (11 papers), Cancer Genomics and Diagnostics (9 papers), PARP inhibition in cancer therapy (8 papers), Hormonal and reproductive studies (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (14.5k citations), Cancer Research (5.0k citations), Oncology (5.3k citations), Radiology, Nuclear Medicine and Imaging (2.6k citations) and Endocrinology, Diabetes and Metabolism (1.4k citations). Dana E. Rathkopf has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Howard I. Scher, Philip W. Kantoff, Min Yuen Teo, Michael J. Morris, Daniel Costin Danila, Steven M. Larson, Celestia S. Higano, Joshi J. Alumkal, Martin Fleisher and Charles L. Sawyers. Their work appears in journals such as Annals of Oncology, European Urology, Clinical Cancer Research, Journal of Clinical Oncology and The Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.